[Clinical results of UFT granule of enteric coating (UFT E granule). Osaka UFT E Granule Study Group]

We carried out a Phase II study by single oral administration of UFT granule of enteric coating (UFT E granule) in 40 patients with breast cancer. One CR and 8 PR cases, of which 34 were evaluable, were obtained, and the response rate was 26.5%.; local 28.6%, lymph node 41.2%, lung 22.2%, bone 14.3%. An average of administration duration was 139 days (28-317 days) for 35 cases. Adverse effects were appeared in 60.0% of the overall, main side effects were anorexia, nausea and vomiting; however, those were not serious. It is concluded that UFT E granule is available for the treatment of breast cancer for long term use.